By comparing hepatic changes between hepAGT+/+ and hepAGT−/− mice, we aimed to elucidate the impact of hepatocyte-derived AGT on NAFLD and its potential mechanisms. This evidence concerns the gene AGT and metabolic dysfunction-associated steatotic liver disease.